Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Medicine"
DOI: 10.1080/07853890.2017.1294761
Abstract: Abstract Background: This study investigated whether levofloxacin-containing concomitant therapy can effectively eradicate Helicobacter pylori infection in patients with type 2 diabetes mellitus (T2DM). Methods: A total of 797 T2DM patients were screened for anti-H. pylori… read more here.
Keywords: eradication; concomitant therapy; levofloxacin containing; therapy ... See more keywords
Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Health-System Pharmacy"
DOI: 10.1093/ajhp/zxy036
Abstract: Purpose This article evaluates the musculoskeletal safety of concomitant therapy with daptomycin and Hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase inhibitors (statins). Summary Often indicated for severe gram-positive infections, daptomycin is commonly administered with statins but there… read more here.
Keywords: concomitant therapy; cpk; patients receiving; statin ... See more keywords
Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease
Sign Up to like & getrecommendations! Published in 2017 at "Inflammatory Bowel Diseases"
DOI: 10.1097/mib.0000000000001212
Abstract: Background: Data on long-term durability of infliximab (IFX) and outcomes of concomitant therapy with immunomodulator in pediatric inflammatory bowel disease are limited. Methods: Children with inflammatory bowel disease who received IFX ± immunomodulator were retrospectively… read more here.
Keywords: concomitant therapy; bowel disease; response; inflammatory bowel ... See more keywords
Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm12111918
Abstract: Tegoprazan, a novel potassium-competitive acid blocker, is currently available for the treatment of Helicobacter pylori infection. We compared the efficacies of tegoprazan-based triple and concomitant therapies in a real-world practice. Data of patients treated with… read more here.
Keywords: based triple; concomitant therapy; therapy; day tegoprazan ... See more keywords